Remission is commonly misconstrued as a definitive endpoint, yet many survivors experience lasting physiologic and psychosocial sequelae that preclude a return to pre-diagnosis “normal.” ...
The U.S. Food and Drug Administration’s approval of Rasonque (daraxonrasib) represents an important advance for patients with ...